<DOC>
	<DOCNO>NCT00613730</DOCNO>
	<brief_summary>This phase II , multi-center , open-label , single-arm clinical trial conduct United States . In approximately 55 center , approximately 75 eligible locally advanced unresectable metastatic pancreatic cancer subject enrol receive first-line therapy gemcitabine panitumumab .</brief_summary>
	<brief_title>Adenocarcinoma Pancreas Treated With Panitumumab Gemcitabine Regimen Investigate Overall Survival Primary Endpoint</brief_title>
	<detailed_description>Enrollment close 3 patient enrol . This voluntary action prompt announcement Southwest Oncology Group ( SWOG ) S0205 trial ( NCT00075686 ) , A Phase III Randomized Open Label Study Comparing Gemcitabine Plus Cetuximab ( IMC-C225 ) Versus Gemcitabine First-Line Therapy Patients Advanced Pancreas Cancer , meet primary endpoint improve overall survival ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Men woman ≥ 18 ≤ 75 year age Histologically cytologically confirm pancreatic adenocarcinoma meet one follow criterion : Locally advance unresectable disease , metastatic disease Measurable unmeasurable disease Patients unresectable pancreatic cancer surgery ( exploratory laparotomy , bilary , gastrointestinal bypass ) eligible , patient fully recover surgery ≥ 28 day pass since operation . Patients history pancreatoduodenectomy eligible provide radiographically documented disease recurrence Karnofsky performance score ≥ 60 % Life expectancy ≥ 12 week document investigator Hematologic function , follow : Absolute neutrophils count ( ANC ) ≥ 1.5 x 10^9/L , platelet count ≥ 100 x 10^9/L , hemoglobin ≥ 9.0 g/dL Renal function , follow : Serum creatinine ≤ 1.5 mg/dL Hepatic function , follow : Aspartate aminotransferase ( AST ) ≤ 3 x upper limit normal ( ULN ) ( liver metastasis ≤ 5 x ULN ) , alanine aminotransferase ( ALT ) ≤ 3 x ULN ( liver metastasis ≤ 5 x ULN ) , total bilirubin ≤ 2.0 mg/dL . Patients history biliary obstruction eligible intervention , criterion meet . Metabolic function , follow : Magnesium ≥ low limit normal , calcium ≥ low limit normal Competent comprehend , sign , date International Ethics Committee/Institutional Review board ( IEC/IRB ) approve informed consent form Islet cell acinar cell carcinoma cystadenocarcinoma History know presence central nervous system ( CNS ) mestatases History another primary cancer , except : Curatively treat cervical carcinoma situ , curatively resect nonmelanomatous skin cancer , primary solid tumor curatively treat know active disease present treatment administer ≥ 3 year prior enrollment Other concurrent anticancer chemotherapy Concomitant malignant disease Prior radiotherapy ≤ 14 day , subject recover radiotherapy Uncontrolled seizure disorder serious neurological disease Any comorbid disease would increase risk toxicity Prior antiEpidermal growth factor receptor ( EGFr ) antibody Vascular endothelial growth factor ( VEGF ) therapy ( eg , cetuximab , bevacizumab ) treatment small molecule EGFr inhibitor ( eg , gefitinib , erlotinib , lapatinib ) Adjuvant chemotherapy chemoradiotherapy ≥ 24 week prior enrollment Prior treatment gemcitabine Patients require chronic use immunosuppressive agent ( eg , methotrexate , cyclosporine , corticosteroid ) Regular use ( determined investigator ) nonsteroidal antiinflammatory agent Known allergy panitumumab component panitumumab formulation gemcitabine Recent infection require course systemic antiinfectives complete ≤ 14 day enrollment ( exception make judgment investigator oral treatment uncomplicated urinary tract infection [ UTI ] ) Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year prior enrollment History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis evidence interstitial lung disease ) screen chest xray compute tomography ( CT ) scan Pulmonary embolism , deep vein thrombosis , significant thromboembolic event ≤ 8 week prior enrollment Preexisting bleed diathesis coagulopathy exception wellcontrolled chronic anticoagulation ( eg , coumadin heparin therapy ) . Patients receive coumadin International Normalized Ratio ( INR ) monitor closely History medical psychiatric condition addictive disorder , laboratory abnormality , opinion investigator , may increase risk associate study participation study drug administration may interfere conduct study interpretation study result Patient unwilling unable comply study requirement Patient pregnant breast feed Man woman child bear potential ( woman post menopausal &lt; 52 week , surgically sterilize , abstinent ) consent use adequate contraceptive precaution ( per institutional standard care ) course study 24 week woman 4 week men , last dose gemcitabine panitumumab , whichever dose last Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection Major surgery ≤ 28 day minor surgery ≤ 14 day prior enrollment Documented history alcohol , cocaine intravenous drug abuse ≤ 6 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>